Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: billkirn who wrote (3378)	12/19/1997 12:41:00 PM
From: JOHN W.	Read Replies (2) \| Respond to of 6136

Quote from PW: " Relative to other biotechnology products, Viracept has achieved one of the best market launches with an annual run revenue rate of approximately $300 million after only eight months. Amgen's (AMGN $53 9/16) Neupogen recorded sales of approximately $232 million in its first year on the market while Centocor's (CNTO $31 1/2) ReoPro achieved approximately $140 million in sales in its first year (marketed by partner, Eli Lilly (LLY $67 1/8)."